Related Experiment Video

Updated: May 29, 2026

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

STAT3 Inhibition by Microtubule-Targeted Drugs: Dual Molecular Effects of Chemotherapeutic Agents

Sarah R Walker1, Mousumi Chaudhury, David A Frank

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, and Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Molecular and Cellular Pharmacology
|September 28, 2011
PubMed

Insights

Microtubule-targeting drugs like paclitaxel inhibit STAT3 phosphorylation, a key factor in cancer cell growth. This interaction offers a new strategy for developing more effective targeted cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Signal transducer and activator of transcription 3 (STAT3) is crucial for cancer cell proliferation and survival.
  • STAT3's association with the cytoskeleton suggests a potential link to microtubule-targeted therapies.
  • STAT3 is frequently activated in cancers like breast and ovarian cancer, which often respond to microtubule drugs.

Purpose of the Study:

  • To investigate the effect of microtubule-targeting agents on STAT3 activity in tumor cells.
  • To explore the mechanism by which these agents inhibit STAT3.
  • To assess the potential of combining microtubule agents with STAT3-targeting drugs for cancer treatment.

Main Methods:

  • Treatment of tumor cells with microtubule stabilizers (e.g., paclitaxel) and inhibitors (e.g., vinorelbine).
  • Assessment of STAT3 tyrosine phosphorylation and expression of STAT3 target genes.
  • Analysis of STAT3-microtubule association and the role of negative feedback regulators.
  • Evaluation of the cytotoxic effects of paclitaxel and its combination with other agents.

Main Results:

  • Microtubule agents significantly decreased STAT3 activating phosphorylation and inhibited STAT3 target gene expression.
  • Paclitaxel reduced STAT3-microtubule association and appeared to inhibit STAT3 via a negative feedback mechanism.
  • The cytotoxic effect of paclitaxel correlated with STAT3 phosphorylation inhibition; 5-azacytidine restored drug sensitivity in resistant cells.
  • Combination therapy of paclitaxel with STAT3 inhibitors demonstrated enhanced killing of STAT3-dependent cancer cells.

Conclusions:

  • Microtubule-targeted agents may exert anti-cancer effects, in part, by inhibiting STAT3 signaling.
  • Understanding the interplay between microtubules and STAT3 is vital for optimizing rational, targeted cancer therapies.
  • This research highlights a potential therapeutic strategy combining microtubule agents with direct STAT3 inhibitors.

More Related Videos

Spatiotemporal Subcellular Manipulation of the Microtubule Cytoskeleton in the Living Preimplantation Mouse Embryo using Photostatins08:13

Spatiotemporal Subcellular Manipulation of the Microtubule Cytoskeleton in the Living Preimplantation Mouse Embryo using Photostatins

Published on: November 30, 2021

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Destabilization of Microtubules01:45

Destabilization of Microtubules

The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...